ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings

SPRY·Reported May 14, 2025·Before market open

ARS Pharmaceuticals, Inc. reported Q1 2025 revenue of $8.0M, missed analyst consensus of $14.7M by $6.7M. Diluted EPS came in at $-0.35 (-218.2% YoY).

Revenue
$8.0Mmissed by $6.7M
Consensus: $14.7M
Diluted EPS
$-0.35met estimate
Consensus: $-0.35
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-25-070900

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about ARS Pharmaceuticals, Inc.'s Q1 2025 earnings report.

ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2025 earnings on May 14, 2025 before market open.

ARS Pharmaceuticals, Inc. reported revenue of $8.0M and diluted EPS of $-0.35 for Q1 2025.

Revenue missed the consensus estimate of $14.7M by $6.7M. EPS beat the consensus estimate of $-0.35 by $0.00.

Compared to the same quarter a year prior, diluted EPS declined 218.2% from $-0.11.

You can read the 10-Q periodic report (0000950170-25-070900) directly on SEC EDGAR. The filing index links above go to sec.gov.